amiodarone has been researched along with Liver Neoplasms in 21 studies
Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.
amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.
Liver Neoplasms: Tumors or cancer of the LIVER.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The results of this study suggest that lipiodol transarterial chemoembolisation with anthracycline and amiodarone was safe but did not increase survival compared with lipiodol transarterial chemoembolisation with anthracycline alone in patients with hepatocellular carcinoma." | 9.15 | Randomised controlled trial of lipiodol transarterial chemoembolisation with or without amiodarone for unresectable hepatocellular carcinoma. ( Bedenne, L; Bonnetain, F; Boulin, M; Cercueil, JP; Chauffert, B; Ciboulet, A; Gagnaire, A; Guiu, B; Hillon, P; Jouve, JL; Krause, D; Lepage, C; Maillard, E; Minello, A, 2011) |
| " Administration of amiodarone for atrial fibrillation led to the development of hyperthyroidism." | 7.73 | Amiodarone-induced hyperthyroidism in a patient with functioning papillary carcinoma of the thyroid and extensive hepatic metastases. ( Mackie, GC; Shulkin, BL, 2005) |
| "Amiodarone is a multidrug resistance inhibitor." | 5.32 | [Sustained clinical response of large hepatocellular carcinoma after chemoembolization with pirarubicin, amiodarone and Lipiodol]. ( Bedenne, L; Cercueil, JP; Chauffert, B; Ferrant, E; Flesch, M; Isambert, N; Jouve, JL; Krause, D, 2004) |
| "The results of this study suggest that lipiodol transarterial chemoembolisation with anthracycline and amiodarone was safe but did not increase survival compared with lipiodol transarterial chemoembolisation with anthracycline alone in patients with hepatocellular carcinoma." | 5.15 | Randomised controlled trial of lipiodol transarterial chemoembolisation with or without amiodarone for unresectable hepatocellular carcinoma. ( Bedenne, L; Bonnetain, F; Boulin, M; Cercueil, JP; Chauffert, B; Ciboulet, A; Gagnaire, A; Guiu, B; Hillon, P; Jouve, JL; Krause, D; Lepage, C; Maillard, E; Minello, A, 2011) |
| "Atypical manifestations of pulmonary toxicity and previously unreported autonomic nervous system dysfunction complicating amiodarone therapy were observed in a patient being treated for sustained ventricular tachycardia." | 4.77 | Atypical pulmonary and neurologic complications of amiodarone in the same patient. Report of a case and review of the literature. ( Estes, NA; Mack, KD; Manolis, AS; Tordjman, T, 1987) |
| " Administration of amiodarone for atrial fibrillation led to the development of hyperthyroidism." | 3.73 | Amiodarone-induced hyperthyroidism in a patient with functioning papillary carcinoma of the thyroid and extensive hepatic metastases. ( Mackie, GC; Shulkin, BL, 2005) |
| "Amiodarone is a well-known antiarrhythmic drug with side effects including phospholipidosis." | 1.62 | Analysis of the intracellular localization of amiodarone using live single-cell mass spectrometry. ( Mizuno, H; Sugiyama, E; Todoroki, K; Yahata, K, 2021) |
| "Nonalcoholic fatty liver disease (NAFLD) is characterized by excessive deposition of droplets in hepatocytes." | 1.51 | Immunohistochemical expression of autophagosome markers LC3 and p62 in preneoplastic liver foci in high fat diet-fed rats. ( Eguchi, A; Ichikawa, R; Masuda, S; Mizukami, S; Nakamura, K; Nakamura, M; Okada, R; Shibutani, M; Tanaka, T; Yoshida, T, 2019) |
| "The prediction of drug-drug interactions mediated by the induction or inhibition of cytochrome P450 enzymes is of great relevance in the development of new drugs." | 1.40 | HepaRG cell line as an in vitro model for screening drug-drug interactions mediated by metabolic induction: amiodarone used as a model substance. ( Alves, G; Falcão, A; Ferreira, A; Rodrigues, M; Silvestre, S, 2014) |
| "Amiodarone induced hepatomegaly, hepatocyte microvesicular lipid accumulation, and a significant decrease in serum triglycerides and glucose." | 1.32 | Disruption of hepatic lipid homeostasis in mice after amiodarone treatment is associated with peroxisome proliferator-activated receptor-alpha target gene activation. ( Hanniman, EA; McCarthy, TC; Pollak, PT; Sinal, CJ, 2004) |
| "Amiodarone is a multidrug resistance inhibitor." | 1.32 | [Sustained clinical response of large hepatocellular carcinoma after chemoembolization with pirarubicin, amiodarone and Lipiodol]. ( Bedenne, L; Cercueil, JP; Chauffert, B; Ferrant, E; Flesch, M; Isambert, N; Jouve, JL; Krause, D, 2004) |
| "Amiodarone and EMD 21388 were without effect both in cytosol and nuclear extract." | 1.29 | Drug competition for intracellular triiodothyronine-binding sites. ( Barlow, JW; Curtis, AJ; Loidl, NM; Raggatt, LE; Stockigt, JR; Topliss, DJ, 1994) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (14.29) | 18.7374 |
| 1990's | 3 (14.29) | 18.2507 |
| 2000's | 6 (28.57) | 29.6817 |
| 2010's | 8 (38.10) | 24.3611 |
| 2020's | 1 (4.76) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, ST | 1 |
| Hsu, WF | 1 |
| Huang, HS | 1 |
| Yen, JH | 1 |
| Lin, MC | 1 |
| Peng, CY | 1 |
| Yen, HR | 1 |
| Yahata, K | 1 |
| Mizuno, H | 1 |
| Sugiyama, E | 1 |
| Todoroki, K | 1 |
| Masuda, S | 1 |
| Mizukami, S | 1 |
| Eguchi, A | 1 |
| Ichikawa, R | 1 |
| Nakamura, M | 1 |
| Nakamura, K | 1 |
| Okada, R | 1 |
| Tanaka, T | 1 |
| Shibutani, M | 1 |
| Yoshida, T | 1 |
| Lan, SH | 1 |
| Wu, SY | 1 |
| Zuchini, R | 1 |
| Lin, XZ | 1 |
| Su, IJ | 1 |
| Tsai, TF | 1 |
| Lin, YJ | 1 |
| Wu, CT | 1 |
| Liu, HS | 1 |
| Ferreira, A | 1 |
| Rodrigues, M | 1 |
| Silvestre, S | 1 |
| Falcão, A | 1 |
| Alves, G | 1 |
| Maimone, S | 1 |
| Filomia, R | 1 |
| Saitta, C | 1 |
| Raimondo, G | 1 |
| Squadrito, G | 1 |
| Guiu, B | 2 |
| Colin, C | 1 |
| Cercueil, JP | 4 |
| Loffroy, R | 1 |
| Guiu, S | 1 |
| Ferrant, E | 2 |
| Jouve, JL | 3 |
| Bonnetain, F | 2 |
| Boulin, M | 2 |
| Ghiringhelli, F | 1 |
| Minello, A | 2 |
| Hillon, P | 3 |
| Bedenne, L | 6 |
| Krause, D | 4 |
| Chauffert, B | 6 |
| Niklas, J | 1 |
| Noor, F | 1 |
| Heinzle, E | 1 |
| Anthérieu, S | 1 |
| Rogue, A | 1 |
| Fromenty, B | 1 |
| Guillouzo, A | 1 |
| Robin, MA | 1 |
| von Vital, JM | 1 |
| Karachristos, A | 1 |
| Singhal, A | 1 |
| Thomas, R | 1 |
| Jain, A | 1 |
| Ciboulet, A | 1 |
| Maillard, E | 1 |
| Gagnaire, A | 1 |
| Lepage, C | 1 |
| McCarthy, TC | 1 |
| Pollak, PT | 1 |
| Hanniman, EA | 1 |
| Sinal, CJ | 1 |
| Isambert, N | 2 |
| Flesch, M | 1 |
| Mackie, GC | 1 |
| Shulkin, BL | 1 |
| Barlow, JW | 1 |
| Curtis, AJ | 1 |
| Raggatt, LE | 1 |
| Loidl, NM | 1 |
| Topliss, DJ | 1 |
| Stockigt, JR | 1 |
| Bakker, O | 1 |
| Hudig, F | 1 |
| Meijssen, S | 1 |
| Wiersinga, WM | 1 |
| Favoulet, P | 1 |
| Faure, P | 1 |
| Osmak, L | 1 |
| Beltramo, JL | 1 |
| Cognet, F | 1 |
| Seitz, JF | 1 |
| Renard, P | 1 |
| Conroy, T | 1 |
| Rougier, P | 1 |
| Lorcerie, B | 1 |
| Faivre, J | 1 |
| Klepping, C | 1 |
| Martin, F | 1 |
| Adler, M | 1 |
| Ros, P | 1 |
| Cremer, M | 1 |
| Quiriny, M | 1 |
| Henry, JP | 1 |
| Lecocq, E | 1 |
| Manolis, AS | 1 |
| Tordjman, T | 1 |
| Mack, KD | 1 |
| Estes, NA | 1 |
2 reviews available for amiodarone and Liver Neoplasms
| Article | Year |
|---|---|
[Drug-induced hepatic lesions].
Topics: Adenoma; Amiodarone; Amphetamines; Antineoplastic Agents; Budd-Chiari Syndrome; Carcinoma, Hepatocel | 1986 |
Atypical pulmonary and neurologic complications of amiodarone in the same patient. Report of a case and review of the literature.
Topics: Aged; Amiodarone; Autonomic Nervous System Diseases; Diagnosis, Differential; Female; Humans; Hypote | 1987 |
2 trials available for amiodarone and Liver Neoplasms
| Article | Year |
|---|---|
Randomised controlled trial of lipiodol transarterial chemoembolisation with or without amiodarone for unresectable hepatocellular carcinoma.
Topics: Adult; Aged; Amiodarone; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 2011 |
Phase II evaluation of doxorubicin plus amiodarone in advanced hepatocarcinoma.
Topics: Adult; Aged; Amiodarone; Carcinoma, Hepatocellular; Doxorubicin; Drug Evaluation; Drug Therapy, Comb | 1991 |
17 other studies available for amiodarone and Liver Neoplasms
| Article | Year |
|---|---|
Improved Survival in Hepatocellular Carcinoma Patients with Cardiac Arrhythmia by Amiodarone Treatment through Autophagy.
Topics: Aged; Amiodarone; Arrhythmias, Cardiac; Autophagy; Carcinoma, Hepatocellular; Cell Survival; Female; | 2019 |
Analysis of the intracellular localization of amiodarone using live single-cell mass spectrometry.
Topics: Amiodarone; Anti-Arrhythmia Agents; Hep G2 Cells; Humans; Liver Neoplasms; Mass Spectrometry | 2021 |
Immunohistochemical expression of autophagosome markers LC3 and p62 in preneoplastic liver foci in high fat diet-fed rats.
Topics: Amiodarone; Animals; Autophagosomes; Autophagy; Autophagy-Related Protein 5; Chloroquine; Diet, High | 2019 |
Autophagy suppresses tumorigenesis of hepatitis B virus-associated hepatocellular carcinoma through degradation of microRNA-224.
Topics: Amiodarone; Animals; Autophagy; Carcinogenesis; Carcinoma, Hepatocellular; Disease Models, Animal; D | 2014 |
HepaRG cell line as an in vitro model for screening drug-drug interactions mediated by metabolic induction: amiodarone used as a model substance.
Topics: Amiodarone; Carcinoma, Hepatocellular; Cell Line, Tumor; Cytochrome P-450 Enzyme System; Drug Intera | 2014 |
Case Report: Atrial Fibrillation After Intravenous Administration of Iodinated Contrast Medium in a Patient With Hepatocellular Carcinoma.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Benzamides; Carcinoma, Hepatocellular | 2015 |
Pilot study of transarterial chemoembolization with pirarubicin and amiodarone for unresectable hepatocellular carcinoma.
Topics: Aged; Aged, 80 and over; Amiodarone; Antineoplastic Agents; Carcinoma, Hepatocellular; Chemoemboliza | 2009 |
Effects of drugs in subtoxic concentrations on the metabolic fluxes in human hepatoma cell line Hep G2.
Topics: Amiodarone; Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Chromatography, High Pr | 2009 |
Induction of vesicular steatosis by amiodarone and tetracycline is associated with up-regulation of lipogenic genes in HepaRG cells.
Topics: Amiodarone; Carcinoma, Hepatocellular; Carrier Proteins; Cell Line, Tumor; Down-Regulation; Fatty Ac | 2011 |
Acute amiodarone hepatotoxicity after liver transplantation.
Topics: Acute Disease; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Carcinoma, Hepatocellular; C | 2011 |
Disruption of hepatic lipid homeostasis in mice after amiodarone treatment is associated with peroxisome proliferator-activated receptor-alpha target gene activation.
Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Blood Glucose; Blotting, Northern; Body Weight; Cell Li | 2004 |
[Sustained clinical response of large hepatocellular carcinoma after chemoembolization with pirarubicin, amiodarone and Lipiodol].
Topics: alpha-Fetoproteins; Amiodarone; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Contrast | 2004 |
Amiodarone-induced hyperthyroidism in a patient with functioning papillary carcinoma of the thyroid and extensive hepatic metastases.
Topics: Aged; Amiodarone; Carcinoma, Papillary; Humans; Hyperthyroidism; Liver Neoplasms; Male; Thyroid Neop | 2005 |
Drug competition for intracellular triiodothyronine-binding sites.
Topics: Amiodarone; Animals; Anti-Inflammatory Agents, Non-Steroidal; Binding Sites; Binding, Competitive; C | 1994 |
Effects of triiodothyronine and amiodarone on the promoter of the human LDL receptor gene.
Topics: Amiodarone; Anti-Arrhythmia Agents; Carcinoma, Hepatocellular; Gene Expression; Humans; Liver Neopla | 1998 |
Increased cytotoxicity and stability of Lipiodol-pirarubicin emulsion compared to classical doxorubicin-Lipiodol: potential advantage for chemoembolization of unresectable hepatocellular carcinoma.
Topics: Amiodarone; Antibiotics, Antineoplastic; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; | 2001 |
[Advanced hepatocellular carcinoma: value of systemic chemotherapy combining adriamycin, amiodarone and 5-fluorouracil].
Topics: Adult; Aged; Amiodarone; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; | 1989 |